Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    21146205 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
2 Unknown  VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Dexamethasone;   Procedure: Peripheral Blood Stem Cell (PBSC) collection;   Procedure: First Autologous Transplantation;   Procedure: Second Autologous Transplantation

Indicates status has not been verified in more than two years